Merck’s first-quarter results exceeded analyst expectations, driven by robust sales of its cancer immunotherapy Keytruda and new product launches. The pharmaceutical company reported revenues of $16.29 billion, surpassing the $15.82 billion forecast, while adjusted losses per share came in at $1.28, better than the anticipated $1.51. Merck also narrowed its 2026 revenue guidance to between $65.8 billion and $67 billion, reflecting positive foreign exchange impacts and strong underlying business performance.
The notable growth of Keytruda, which generated $8.03 billion in sales—12% higher year-over-year—highlights its increasing uptake for earlier-stage cancers and metastatic cases. Additionally, the newer drug Winrevair showed impressive growth, with sales up 88% to $525 million, indicating strong market acceptance. However, Merck continues to face challenges with its Gardasil vaccine, which saw a 19% decline in sales, underscoring the competitive pressures in the vaccine market.
For market professionals, Merck’s ability to adapt through acquisitions and product diversification is crucial as it navigates impending patent expirations. This strategic focus may enhance investor confidence in its long-term growth trajectory despite short-term losses.
Source: cnbc.com